The stock of BridgeBio Pharma Inc (BBIO) has gone up by 8.05% for the week, with a 34.82% rise in the past month and a 19.43% rise in the past quarter. The volatility ratio for the week is 2.57%, and the volatility levels for the past 30 days are 2.44% for BBIO. The simple moving average for the last 20 days is 15.74% for BBIO stock, with a simple moving average of 42.46% for the last 200 days.
Is It Worth Investing in BridgeBio Pharma Inc (NASDAQ: BBIO) Right Now?
BBIO has 36-month beta value of 1.11. Analysts have mixed views on the stock, with 11 analysts rating it as a “buy,” 6 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for BBIO is 160.74M, and currently, short sellers hold a 13.68% ratio of that float. The average trading volume of BBIO on June 25, 2025 was 2.96M shares.
BBIO) stock’s latest price update
BridgeBio Pharma Inc (NASDAQ: BBIO)’s stock price has surge by 3794290relation to previous closing price of 42.17. Nevertheless, the company has seen a 8.05% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-04 that BridgeBio’s Attruby launch crushed expectations, with Q1 revenue triple analyst estimates, driven by higher-than-expected conversion rates and minimal free trial usage. Competitive threats from Amvuttra appear overstated, as Attruby script declines were minor and BridgeBio management remains confident in market positioning and pricing. My updated model projects 2025 revenues of $728 million, far above consensus, and sees potential for nearly $1 billion in 2026 from existing patients alone.
Analysts’ Opinion of BBIO
Many brokerage firms have already submitted their reports for BBIO stocks, with Wolfe Research repeating the rating for BBIO by listing it as a “Outperform.” The predicted price for BBIO in the upcoming period, according to Wolfe Research is $49 based on the research report published on June 17, 2025 of the current year 2025.
Redburn Atlantic, on the other hand, stated in their research note that they expect to see BBIO reach a price target of $50. The rating they have provided for BBIO stocks is “Buy” according to the report published on March 31st, 2025.
BBIO Trading at 22.22% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 5.33% of gains for the given period.
Insider Trading
Valantine Hannah, the Director of BridgeBio Pharma Inc, sale 4,292 shares at $40.00 during a trade that took place back on Jun 10 ’25, which means that Valantine Hannah is holding 1,764 shares at $171,680 based on the most recent closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -5.48 for the present operating margin
- 0.97 for the gross margin
The net margin for BridgeBio Pharma Inc stands at -5.24. The total capital return value is set at -0.96.
Based on BridgeBio Pharma Inc (BBIO), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -49.43. The debt to equity ratio resting at -0.01. The interest coverage ratio of the stock is -5.91.
Currently, EBITDA for the company is -436.83 million with net debt to EBITDA at 0.96. When we switch over and look at the enterprise to sales, we see a ratio of 62.08. The receivables turnover for the company is 1.11for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.57.
Conclusion
To put it simply, BridgeBio Pharma Inc (BBIO) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
